Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.3 EUR | +7.97% | +13.44% | -27.86% |
Jun. 14 | Abionyx: positive response from FDA, share price rises | CF |
Jun. 13 | ABIONYX Pharma Completes Pre-IND Meeting with the FDA for CER-001 Phase 2b/3 Clinical Trial for Patients with Sepsis | CI |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- One of the major weak points of the company is its financial situation.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-27.86% | 47.06M | - | ||
+18.15% | 124B | B+ | ||
+18.02% | 112B | B+ | ||
+5.07% | 22.94B | B | ||
-12.75% | 22.22B | B+ | ||
-9.86% | 17.02B | B | ||
-14.97% | 16.88B | A- | ||
-39.94% | 16.87B | A- | ||
+2.80% | 13.63B | C+ | ||
+27.39% | 11.61B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- ABNX Stock
- 609 Stock
- Ratings ABIONYX Pharma